Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Nov 11, 2026
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living
Corporate Presentation

SEC Filings

Form Description Filing date View
8-K Report of unscheduled material events or corporate event View HTML
0001193125-26-457244.pdf
0001193125-26-457244.rtf
0001193125-26-457244.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q Quarterly report which provides a continuing view of a company's financial position View HTML
0001193125-26-457280.pdf
0001193125-26-457280.rtf
0001193125-26-457280.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4 Statement of changes in beneficial ownership of securities View HTML
0001193125-26-421529.pdf
0001193125-26-421529.rtf
0001193125-26-421529.xls
144 Filed by "insiders" prior intended sale of restricted stock. View HTML
0001973379-26-000350.pdf
0001973379-26-000350.rtf

Data provided by Kaleidoscope.